New Delhi, September 11, 2024.
Bharat Biotech on Wednesday announced a collaboration with Alopexx Inc for development and commercialisation of the latter’s broad-spectrum anti-microbial vaccine in India and other low income countries.
As part of the collaboration, the companies will co-develop and commercialise the vaccine — AV0328, in India and other licensed territories, Bharat Biotech said in a statement.
Alopexx would be entitled to a one-time upfront payment and milestone payments, as well as royalties on future sales of AV0328 in the licensed territories, it added.